|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4889818A
(en)
|
1986-08-22 |
1989-12-26 |
Cetus Corporation |
Purified thermostable enzyme
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
JPH11514853A
(ja)
|
1995-09-08 |
1999-12-21 |
ジエンザイム コーポレイション |
遺伝子治療のための改良されたaavベクター
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
CA2300957A1
(en)
|
1997-08-15 |
1999-02-25 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
JP2001517454A
(ja)
|
1997-09-19 |
2001-10-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
WO1999043208A1
(en)
|
1998-02-27 |
1999-09-02 |
The General Hospital Corporation |
The helios gene
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6168991B1
(en)
|
1999-06-25 |
2001-01-02 |
Lucent Technologies Inc. |
DRAM capacitor including Cu plug and Ta barrier and method of forming
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
WO2001045737A2
(en)
|
1999-12-22 |
2001-06-28 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
JP4810042B2
(ja)
|
2000-01-21 |
2011-11-09 |
バイオヴェックス リミテッド |
ヘルペスウイルス株
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
NZ527687A
(en)
|
2001-05-11 |
2005-10-28 |
Wellstat Biolog Corp Formerly |
Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
|
|
CA2452517A1
(en)
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
WO2003082200A2
(en)
|
2002-03-27 |
2003-10-09 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
US20050220818A1
(en)
|
2002-06-21 |
2005-10-06 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
|
CA2498297A1
(en)
|
2002-09-09 |
2004-03-18 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
|
ATE539162T1
(de)
|
2003-03-27 |
2012-01-15 |
Ottawa Hospital Res Inst |
Mutierte viren der vesikulären stomatitis und deren verwendung
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
MXPA05013879A
(es)
|
2003-06-18 |
2006-06-27 |
Genelux Corp |
Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
|
|
EP1668143B1
(en)
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
JP2007511216A
(ja)
|
2003-11-17 |
2007-05-10 |
クルセイド ラボラトリーズ リミテッド |
変異ウイルス
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
ES2678094T3
(es)
|
2004-07-10 |
2018-08-08 |
Fox Chase Cancer Center |
Líneas de células asesinas naturales genéticamente modificadas
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
EP2963118B1
(en)
|
2005-06-01 |
2017-08-09 |
California Institute of Technology |
Method of targeted gene delivery using viral vectors
|
|
US8986672B2
(en)
|
2005-06-23 |
2015-03-24 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
EP2415783B1
(en)
|
2006-10-16 |
2016-12-14 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
JP5442452B2
(ja)
|
2007-02-16 |
2014-03-12 |
ウイルツ・バイオロジクス・リミテッド |
単純ヘルペスウイルスおよびウイルス複製法
|
|
US8110379B2
(en)
|
2007-04-26 |
2012-02-07 |
Sangamo Biosciences, Inc. |
Targeted integration into the PPP1R12C locus
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
WO2009041113A1
(ja)
|
2007-09-28 |
2009-04-02 |
Olympus Corporation |
Fc受容体遺伝子導入NK細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
KR101133185B1
(ko)
|
2008-07-29 |
2012-04-06 |
서울대학교병원 |
자연살해세포의 증식방법
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
JP2012521215A
(ja)
|
2009-03-26 |
2012-09-13 |
アヴァリス・アクチエボラーグ |
Nk細胞の増殖
|
|
WO2012061814A1
(en)
|
2010-11-05 |
2012-05-10 |
Transgenomic, Inc. |
Pcr primers and methods for rapid and specific genotyping
|
|
US10066207B2
(en)
|
2012-04-18 |
2018-09-04 |
Board Of Trustees Of Michigan State University |
Natural killer cells with enhanced immune response
|
|
US11471486B2
(en)
*
|
2012-09-04 |
2022-10-18 |
Inven2 As |
Selective and controlled expansion of educated NK cells
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
US9902973B2
(en)
|
2013-04-11 |
2018-02-27 |
Caribou Biosciences, Inc. |
Methods of modifying a target nucleic acid with an argonaute
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
US10813952B2
(en)
|
2014-11-14 |
2020-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
|
|
US20170137784A1
(en)
*
|
2015-03-23 |
2017-05-18 |
Cellex Corporation |
NK Cell Culture Container And NK Cell Culture Method
|
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
|
JP7033453B2
(ja)
|
2015-06-30 |
2022-03-10 |
セレクティス |
特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法
|
|
EP3828266B1
(en)
|
2015-07-29 |
2022-11-23 |
ONK Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
EP3349770A1
(en)
|
2015-09-14 |
2018-07-25 |
Regents of the University of Minnesota |
Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
|
|
CN122146606A
(zh)
|
2015-11-04 |
2026-06-05 |
菲特治疗公司 |
用于诱导造血细胞分化的方法和组合物
|
|
US12642852B1
(en)
|
2015-11-04 |
2026-06-02 |
Fate Therapeutics, Inc. |
Genomic engineering of pluripotent cells
|
|
AU2017210031C1
(en)
|
2016-01-20 |
2020-11-26 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス,インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
EP3487991B1
(en)
*
|
2016-07-25 |
2022-09-07 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of producing modified natural killer cells and methods of use
|
|
AU2018219895C1
(en)
|
2017-02-09 |
2024-10-03 |
Indapta Therapeutics, Inc. |
Engineered Natural Killer (NK) cells and compositions and methods thereof
|
|
EP3539552A1
(en)
|
2018-03-16 |
2019-09-18 |
Deutsches Rheuma-Forschungszentrum Berlin |
Activation and expansion of nkg2c+ nk cells
|
|
JP6543375B1
(ja)
|
2018-03-27 |
2019-07-10 |
株式会社ガイアバイオメディシン |
ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用
|
|
CN112839666A
(zh)
|
2018-05-14 |
2021-05-25 |
因达普塔治疗公司 |
具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
|
|
EP3884041A2
(en)
|
2018-11-21 |
2021-09-29 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (nk) cell subset and related compositions and methods
|